Immuno-oncology
Janux wowed last year with first data from its ‘masked’ T-cell engager, JANX007, but investors have been spooked by newly updated results for the product. Analysts, however, still think it can compete with rivals from Amgen and J&J.
The company plans to take IGV-001 to the FDA after the mid-stage trial showed a more than six-month improvement in overall survival compared with placebo.
Akeso’s first-in-class PD-1/VEG-F bispecific ivonescimab is a landmark achievement for China’s biotech sector, but the firm is already expanding its ambitions in oncology and beyond, including a challenge to Roche in Alzheimer’s.
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.
The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.
Having built its reputation as the ‘Gateway to China’ for global firms, Zai is going global itself, moving its potential first-in-class ADC into Phase III development.
Terms like ‘game-changing’ and ‘transformational’ are regularly used by pharma companies but the data behind the latest approval for the Padcev/Keytruda combo for adults with muscle- invasive bladder cancer who are ineligible for cisplatin has been heralded by KOLs as exactly that.
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
The company announced topline results from its Phase III trial in gastroesophageal adenocarcinoma and plans to seek US FDA approval in the first half of 2026.
The German company is on a roll, early data on a pair of new T cell receptors adding to its promising lead cell therapy which impressed at ESMO.
Byterna, Starna, Vivacta and DeliNova ride surging investor sentiment on in vivo CAR-T assets to secure venture funding.
The company announced data from patients enrolled after a protocol amendment designed to bring the study in line with non-muscle invasive bladder cancer (NMIBC) standards of care.
Newly revealed data on HLX43’s recommended Phase II/III dose has boosted Henlius’s confidence to launch up to eight Phase III trials of the ADC in lung cancer. Phase III trials of the agent in more cancer types are also on the horizon.
New CEO, Eran Ophir, is banking on positive readouts from AstraZeneca and Arcus’s TIGIT programs soon validating its science as it pushes ahead with its immuno-oncology pipeline in a field littered with disappointments.
In a China-only Phase III trial, Sichuan Kelun-Biotech’s sac-TMT significantly cut the risk of death by 40% versus chemotherapy in the second-line treatment of non-squamous EGFR-mutated NSCLC. The ADC was administered at a higher dose than in Merck’s multiple Phase III trials of the same agent.
Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.
The company presented detailed data at ESMO and said its Phase III trial might have reached statistical significance with a larger sample size.